Piramal Pharma Quarterly Results for Trading Insights
In Mar 2026, Piramal Pharma (PPLPHARMA) reported revenue ₹2,811 Cr and net profit ₹-9 Cr — revenue 0.0% YoY. View PPLPHARMA 52-week performance for the annual high/low range and current price position.
PPLPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Piramal Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse PPLPHARMA promoter holding to track promoter, FII and institutional holdings.
- Revenue of ₹2,811 Cr in Mar 2026 (+18.2% vs Jun 2026, -0.0% vs Mar 2025)
- Net Profit of ₹-9 Cr in Mar 2026 (+87.0% vs Jun 2026, -105.8% vs Mar 2025)
- EBITDA of ₹344 Cr in Mar 2026 (+13.2% vs Jun 2026)
- Operating Margin of 10.0% in Mar 2026 (+1.0pp vs Jun 2026)
- Earnings Per Share of ₹-0.07 in Mar 2026 (+86.5% vs Jun 2026)
Piramal Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
PPLPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 2,811 | 2,379 | 2,124 | 2,812 | 2,031 | 18.2% | 0.0% |
| Net Profit (₹ Cr) | -9 | -69 | -99 | 154 | -82 | - | - |
| EBITDA (₹ Cr) | 344 | 304 | 239 | 619 | 204 | - | - |
| EPS (₹) | -0.07 | -0.52 | -0.75 | 1.16 | -0.62 | - | - |
| Operating Margin (%) | 10.0% | 9.0% | 8.0% | 20.0% | 6.0% | - | - |
PPLPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Piramal Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit PPLPHARMA share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
PPLPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Piramal Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores